BioScrip Inc. (NASDAQ:BIOS) shot up 2.3% on Friday . The stock traded as high as $2.65 and last traded at $2.63, with a volume of 58,834 shares traded. The stock had previously closed at $2.57.

Separately, Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.

The stock’s market capitalization is $300.64 million. The firm’s 50 day moving average price is $2.68 and its 200 day moving average price is $2.49.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to the consensus estimate of $229.58 million. The company’s quarterly revenue was down 11.4% compared to the same quarter last year. On average, equities analysts expect that BioScrip Inc. will post ($0.27) EPS for the current year.

In related news, Director Coliseum Capital Management, L bought 4,200,000 shares of the stock in a transaction dated Wednesday, June 22nd. The stock was acquired at an average price of $2.00 per share, for a total transaction of $8,400,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David W. Golding bought 12,500 shares of the stock in a transaction dated Friday, June 17th. The stock was bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the purchase, the director now owns 42,500 shares of the company’s stock, valued at approximately $105,400. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.